stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) Return on assets
BioMarin Pharmaceutical Inc.'s return on assets over the twelve months to 30 September 2026 was −0.20%, down 5.0 percentage points from fiscal 2025 (4.79%). Over the past ten years it has ranged from −16.3% (fiscal 2016) to 16.2% (fiscal 2020); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 4.79% | (1.38) |
| FY2024 | 6.17% | 3.63 |
| FY2023 | 2.54% | 0.25 |
| FY2022 | 2.29% | 3.37 |
| FY2021 | −1.08% | (17.29) |
| FY2020 | 16.2% | 16.73 |
| FY2019 | −0.52% | 1.18 |
| FY2018 | −1.70% | 1.00 |
| FY2017 | −2.70% | 13.56 |
| FY2016 | −16.3% | (10.72) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 37.7% |
| CAI Caris Life Sciences,�Inc. compare | 8.58% |
| TECH Bio-Techne Corp compare | 7.07% |
| BMRN BioMarin Pharmaceutical Inc. | −0.20% |
| TWST Twist Bioscience Corporation compare | −20.8% |
| KYMR Kymera Therapeutics, Inc. compare | −24.4% |
| PCVX Vaxcyte, Inc. compare | −33.0% |
| SMMT Summit Therapeutics PLC compare | −159.1% |
| IBRX ImmunityBio, Inc. compare | −192.6% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BMRN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement